Skip to main
LFMD
LFMD logo

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc. has demonstrated notable growth momentum through its weight management program, which has been a key driver of revenue increase in recent quarters. The company is expected to accelerate growth in 2025, supported by its comprehensive telehealth platform that integrates various healthcare services and products. Additionally, the introduction of direct access to Wegovy at a significantly reduced cost could attract more subscribers, further enhancing topline sales for the company.

Bears say

LifeMD Inc. faces significant financial uncertainties that contribute to a negative outlook, primarily due to its reliance on the Telehealth segment for revenue. Key risks include potential lower growth in telehealth revenue, challenges in acquiring and retaining patients, and the company's struggle to achieve profitability amid increasing competition. Additionally, concerns regarding net debt and preferred stock further complicate the financial landscape, indicating possible dilution risks that may affect investor confidence.

LifeMD (LFMD) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Buy based on their latest research and market trends.

According to 5 analysts, LifeMD (LFMD) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.